Siirry päänavigointiin Siirry hakuun Siirry pääsisältöön

Ultra-low-input cell-free DNA sequencing for tumor detection and characterization in a real-world pediatric brain tumor cohort

  • Tom T. Fischer
  • , Kendra K. Maaß*
  • , Pitithat Puranachot
  • , Markus Mieskolainen
  • , Martin Sill
  • , Paulina S. Schad
  • , Stefanie Volz
  • , Fabian Rosing
  • , Tatjana Wedig
  • , Nathalie Schwarz
  • , Agnes M.E. Finster
  • , Florian Iser
  • , Jochen Meyer
  • , Felix Sahm
  • , Olli Lohi
  • , Ahmed El Damaty
  • , Benedikt Brors
  • , Hannu Haapasalo
  • , Stefan M. Pfister
  • , Joonas Haapasalo
  • Kristian W. Pajtler*, Kristiina Nordfors
*Tämän työn vastaava kirjoittaja

Tutkimustuotos: Artikkeli › Tieteellinen › vertaisarvioitu

15 Sitaatiot (Scopus)
10 Lataukset (Pure)

Abstrakti

Molecular profiling of pediatric central nervous system (CNS) tumors has important clinical utility for guiding diagnostic and therapeutic strategies. Cell-free DNA (cfDNA) from liquid biopsies has been used for minimally invasive tumor profiling and longitudinal disease assessment in adult oncology and pediatric hematology. However, in pediatric neuro-oncology, low cfDNA yields pose a major barrier to translating these assays from bench to bedside. Here, we implemented a low-coverage whole genome sequencing (lcWGS) assay for picogram-level cfDNA inputs and applied it to liquid biopsies from a sizeable, population-based, cross-entity pediatric CNS tumor cohort (n = 56 patients). Applying this protocol, cfDNA whole genome profiles were successfully acquired from all liquid biopsy samples (n = 61/61 serum, n = 56/56 CSF, 100%). Based on copy number variations (CNVs), circulating-tumor DNA (ctDNA) was detected in 2/61 serum (3%) and in 25/56 CSF (45%) samples across various brain tumor entities. The integration of cfDNA results with clinical data demonstrated the utility of CSF lcWGS as a biomarker assay at diagnosis to distinguish cancerous from non-cancerous pineal region lesions (n = 6 patients). Additionally, serial CSF assessment in n = 9 patients (n = 29 CSF samples) enabled minimally invasive disease monitoring, with the added value of molecular profile availability in n = 4/6 (67%) patients at relapse. Proof-of-concept data show the feasibility of serial CSF lcWGS to reveal tumor evolution, tumor heterogeneity and potential therapeutic vulnerabilities in a case of medulloblastoma and germ cell tumor. Our study underscores the clinical utility of a robust lcWGS-based liquid biopsy assay optimized for low-input samples. We identify use-cases for implementing liquid biopsies in the clinical management of pediatric CNS tumor patients and provide a strong rationale for integration into future trials.

AlkuperäiskieliEnglanti
Artikkeli134
JulkaisuActa Neuropathologica Communications
Vuosikerta13
Numero1
DOI - pysyväislinkit
TilaJulkaistu - 2025
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

YK:n kestävän kehityksen tavoitteet

Tämä tuotos edistää seuraavia kestävän kehityksen tavoitteita:

  1. SDG 3 – Hyvä terveys ja hyvinvointi
    SDG 3 – Hyvä terveys ja hyvinvointi

Julkaisufoorumi-taso

  • Jufo-taso 1

!!ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Pediatrics, Perinatology, and Child Health

Sormenjälki

Sukella tutkimusaiheisiin 'Ultra-low-input cell-free DNA sequencing for tumor detection and characterization in a real-world pediatric brain tumor cohort'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

Siteeraa tätä